BBV154
AXP000176.1 · Vaccine
- Platform
- chimpanzee adenovirus (non-replicating, intranasal)
- Targets
- SARS-CoV-2 S
- Originator
- Washington University in St. Louis
- Sponsor
- Bharat Biotech
Names
| Name | Type | Source |
|---|---|---|
| BBV154 | preferred name, code | curator, press |
| iNCOVACC | brand | press |
| ChAd-SARS-CoV-2-S ambiguous | code | press |
Virus
- Role
- Vaccine vector
- Family
- Adenoviridae
- Virus
- chimpanzee adenovirus
- Replication
- non replicating
- Modifications
- replication-deficient adenoviral vector encoding a pre-fusion stabilised SARS-CoV-2 spike
- Transgenes
- SARS-CoV-2 spike
- Route
- intranasal
- Source
- evidence
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| other | IN | 2022-09 | conditional | iNCOVACC | Restricted use in emergency situation for prevention of COVID-19 in adults (primary course and heterologous booster) | source |
Clinical trials (4)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05522335 | Phase III Study of BBV154 Intranasal Vaccine in Healthy Volunteers | Unknown | Phase 3 | 2022-04-16 | 2022-07-19 | 3160 | COVID-19 Respiratory Infection |
| NCT05567471 | Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster Dose | Completed | Phase 3 | 2022-02-26 | 2022-05-03 | 875 | COVID-19 Respiratory Infection |
| NCT05639998 | BBV152/BBV154 Heterologus Prime-Boost Study | Completed | Phase 2 | 2021-09-01 | 2022-03-01 | 608 | Corona Virus Infection |
| NCT04751682 | Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19 | Completed | Phase 1 | 2021-03-01 | 2021-06-25 | 175 | SARS-CoV Infection |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 36435633 | Nasal vaccines: solutions for respiratory infectious diseases. | Trends in molecular medicine | 2023 | cited by trial NCT05522335 |
| PMID 37596281 | Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®). | NPJ vaccines | 2023 | cited by trial NCT05522335 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40269252 | Effect of heterologous intranasal iNCOVACC® vaccination as a booster to two-dose intramuscular Covid-19 vaccination series: a randomized phase 3 clinical trial. | Communications medicine | 2025 | name in title: iNCOVACC |
| PMID 38337035 | Mucosal vaccine-induced cross-reactive CD8+ T cells protect against SARS-CoV-2 XBB.1.5 respiratory tract infection. | Nature immunology | 2024 | name in abstract: iNCOVACC |
| PMID 37205450 | A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 infection and disease in mice and hamsters. | bioRxiv : the preprint server for biology | 2023 | name in abstract: iNCOVACC |
| PMID 36569867 | Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152). | Frontiers in immunology | 2022 | name in title: BBV154 |
Unconfirmed matches (1)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39083604 | Mucosal immunization with ChAd-SARS-CoV-2-S prevents sequential transmission of SARS-CoV-2 to unvaccinated hamsters. | Science advances | 2024 | name in title: ChAd-SARS-CoV-2-S |
Notes
iNCOVACC: replication-deficient adenovirus-vectored vaccine encoding a pre-fusion stabilised SARS-CoV-2 spike, given as nasal drops. Constructs were designed at Washington University in St. Louis (where the vector is described as a chimpanzee adenovirus, ChAd-SARS-CoV-2-S); the Indian regulator granted restricted use in an emergency situation for adults, announced on 6 September 2022, both as a primary two-dose course and as a heterologous booster. The source read does not name the chimpanzee adenovirus serotype, so the strain cell is left empty.
How to cite
BBV154 (AXP000176.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000176.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.